Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow SRPT
Sarepta Therapeutics, Inc. (SRPT) EV/Sales
As of 16 October 2026, Sarepta Therapeutics, Inc. (SRPT) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from 0.6× (July 2025) to 283× (September 2016); the current reading is higher than 6% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.0× | (83.84%) |
| FY2024 | 6.0× | (11.56%) |
| FY2023 | 6.8× | (39.60%) |
| FY2022 | 11.3× | 25.12% |
| FY2021 | 9.0× | (60.71%) |
| FY2020 | 22.9× | (3.81%) |
| FY2019 | 23.8× | 10.47% |
| FY2018 | 21.5× | 19.89% |
| FY2017 | 18.0× | (83.26%) |
| FY2016 | 107× | (27.74%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | (11.65%) |
| Mar 2026 | 1.2× | 20.70% |
| Dec 2025 | 1.0× | 6.23% |
| Sep 2025 | 0.9× | 7.71% |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −2.2× |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. | 1.0× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.3× |
| URGN Urogen Pharma compare | 9.7× |
| AGIO Agios Pharmaceuticals, Inc. compare | 12.7× |
| PVLA Palvella Therapeutics, Inc. compare | 35.6× |
| ZYME Zymeworks Inc. compare | 42.0× |
| MESO Mesoblast Limited compare | 137× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)